{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:47:28Z","timestamp":1789706848831,"version":"4.0.1"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.13383","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T15:32:23Z","timestamp":1623425543000},"page":"e2113383","source":"Crossref","is-referenced-by-count":13,"title":["Trends in Use of Prescription Nonsteroidal Anti-inflammatory Medications Before vs After Implementation of a Florida Law Restricting Opioid Prescribing for Acute Pain"],"prefix":"10.1001","volume":"4","author":[{"given":"Shailina","family":"Keshwani","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanna","family":"Grande","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maguire","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Goodin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Vouri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"},{"name":"UF Health Physicians, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Hincapie-Castillo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"},{"name":"Pain Research and Intervention Center of Excellence, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"issue":"11","key":"zoi210405r1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017-2018.","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi210405r2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.drugalcdep.2018.09.022","article-title":"Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: a national systematic legal review.","volume":"194","author":"Davis","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi210405r5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0234","article-title":"Changes in opioid use after Florida\u2019s restriction law for acute pain prescriptions.","volume":"3","author":"Hincapie-Castillo","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi210405r6","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.jval.2020.04.323","article-title":"PDG33 changes in Schedule II oral opioid volume dispensed in a private payer following Florida\u2019s acute pain opioid restriction law.","volume":"23","author":"Hincapie-Castillo","year":"2020","journal-title":"Value Health"},{"issue":"January","key":"zoi210405r7","article-title":"Changes in quantity of opioids dispensed following Florida\u2019s restriction law for acute pain prescriptions.","author":"Hincapie-Castillo","year":"2021","journal-title":"Pain Med"},{"issue":"3","key":"zoi210405r8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.surg.2019.04.022","article-title":"Opioid prescriptions for acute pain after outpatient surgery at a large public university-affiliated hospital: impact of state legislation in Florida.","volume":"166","author":"Potnuru","year":"2019","journal-title":"Surgery"},{"issue":"11","key":"zoi210405r9","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1001\/jamainternmed.2018.4273","article-title":"Frequency and associations of prescription nonsteroidal anti-inflammatory drug use among patients with a musculoskeletal disorder and hypertension, heart failure, or chronic kidney disease.","volume":"178","author":"Bouck","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"10","key":"zoi210405r10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2015.9936","article-title":"JAMA patient page: nonsteroidal anti-inflammatory drugs.","volume":"314","author":"Jin","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"zoi210405r11","first-page":"e61","article-title":"Trends in opioid and nonsteroidal anti-inflammatory use and adverse events.","volume":"24","author":"Fassio","year":"2018","journal-title":"Am J Manag Care"},{"issue":"2","key":"zoi210405r12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.18553\/jmcp.2004.10.2.172","article-title":"Need for greater scrutiny of days supply values in DACON calculations.","volume":"10","author":"Lewis","year":"2004","journal-title":"J Manag Care Pharm"},{"issue":"369","key":"zoi210405r14","first-page":"1","article-title":"Prevalence of prescription pain medication use among adults: United States, 2015-2018.","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"2","key":"zoi210405r15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/15360288.2016.1173761","article-title":"Guideline for prescribing opioids for chronic pain.","volume":"30","author":"Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services","year":"2016","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"4","key":"zoi210405r16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/ph3041279","article-title":"Significant acute kidney injury due to non-steroidal anti-inflammatory drugs: inpatient setting.","volume":"3","author":"Dixit","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"zoi210405r17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/DHPS","article-title":"Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies.","volume":"7","author":"Goldstein","year":"2015","journal-title":"Drug Healthc Patient Saf"},{"issue":"9","key":"zoi210405r18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16839","article-title":"Assessment of prescription analgesic use in older adults with and without chronic kidney disease and outcomes.","volume":"3","author":"Han","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi210405r19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.tcm.2016.04.011","article-title":"FDA labeling of NSAIDs: review of nonsteroidal anti-inflammatory drugs in cardiovascular disease.","volume":"26","author":"Pirlamarla","year":"2016","journal-title":"Trends Cardiovasc Med"},{"issue":"5","key":"zoi210405r20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamasurg.2019.5891","article-title":"Disappointing early results from opioid prescribing limits for acute pain.","volume":"155","author":"Chua","year":"2020","journal-title":"JAMA Surg"},{"key":"zoi210405r13","first-page":"171","volume-title":"Experimental and Quasi-experimental Designs for Generalized Causal Inference","author":"William","year":"2002"},{"key":"zoi210405r3","unstructured":"National Conference of State Legislatures. Prescribing policies: states confront opioid overdose epidemic. Accessed November 16, 2020. https:\/\/www.ncsl.org\/research\/health\/prescribing-policies-states-confront-opioid-overdose-epidemic.aspx"},{"key":"zoi210405r4","unstructured":"Fla Stat \u00a7456.44 (2018). Controlled substance prescribing. Accessed November 16, 2020. https:\/\/www.flsenate.gov\/laws\/statutes\/2018\/456.44"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2780923\/keshwani_2021_oi_210405_1623176005.08398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T15:32:37Z","timestamp":1623425557000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2780923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.13383","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}